Veracyte, Inc. (VCYT) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $39.48 (-4.20%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 5, 2026 | Kallum Titchmarsh | Morgan Stanley | $37.00 | -6.3% |
| Jan 5, 2026 | Subbu Nambi | Guggenheim | $50.00 | +26.6% |
| Nov 5, 2025 | Lu Li | UBS | $48.00 | +21.6% |
| Nov 5, 2025 | Kyle Mikson | Canaccord Genuity | $43.00 | +8.9% |
| Oct 20, 2025 | Kyle Mikson | Canaccord Genuity | $40.00 | +1.3% |
| Aug 8, 2025 | Tejas Savant | Morgan Stanley | $28.00 | -29.1% |
| Nov 7, 2024 | Mike Matson | Needham | $44.00 | +11.4% |
| Aug 12, 2024 | Tejas Savant | Morgan Stanley | $26.00 | -34.1% |
Top Analysts Covering VCYT
VCYT vs Sector & Market
| Metric | VCYT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.44 | 2.25 | 2.42 |
| Analyst Count | 18 | 8 | 18 |
| Target Upside | +40.1% | +16187.2% | +19.5% |
| P/E Ratio | 36.64 | 3.75 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $572M | $576M | $578M | 10 |
| 2027-03-31 | $146M | $147M | $150M | 4 |
| 2027-06-30 | $160M | $162M | $164M | 3 |
| 2027-09-30 | $164M | $166M | $168M | 3 |
| 2027-12-31 | $170M | $172M | $174M | 3 |
| 2028-03-31 | $160M | $162M | $164M | 2 |
| 2028-06-30 | $179M | $180M | $183M | 5 |
| 2028-09-30 | $184M | $186M | $189M | 4 |
| 2028-12-31 | $192M | $194M | $197M | 4 |
| 2029-12-31 | $770M | $782M | $791M | 7 |
| 2030-12-31 | $835M | $848M | $858M | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.40 | $1.66 | $1.79 | 7 |
| 2027-03-31 | $0.38 | $0.38 | $0.39 | 3 |
| 2027-06-30 | $0.43 | $0.44 | $0.44 | 2 |
| 2027-09-30 | $0.44 | $0.45 | $0.46 | 2 |
| 2027-12-31 | $0.47 | $0.48 | $0.49 | 2 |
| 2028-03-31 | $0.34 | $0.34 | $0.35 | 3 |
| 2028-06-30 | $0.42 | $0.43 | $0.43 | 6 |
| 2028-09-30 | $0.44 | $0.44 | $0.45 | 5 |
| 2028-12-31 | $0.48 | $0.49 | $0.50 | 5 |
| 2029-12-31 | $1.99 | $2.03 | $2.06 | 1 |
| 2030-12-31 | $2.09 | $2.13 | $2.16 | 1 |
Frequently Asked Questions
What is the analyst consensus for VCYT?
The consensus among 18 analysts covering Veracyte, Inc. (VCYT) is Buy with an average price target of $57.83.
What is the highest price target for VCYT?
The highest price target for VCYT is $50.00, set by Subbu Nambi at Guggenheim on 2026-01-05.
What is the lowest price target for VCYT?
The lowest price target for VCYT is $26.00, set by Tejas Savant at Morgan Stanley on 2024-08-12.
How many analysts cover VCYT?
18 analysts have issued ratings for Veracyte, Inc. in the past 12 months.
Is VCYT a buy or sell right now?
Based on 18 analyst ratings, VCYT has a consensus rating of Buy (2.44/5) with a +40.1% upside to the consensus target of $57.83.
What are the earnings estimates for VCYT?
Analysts estimate VCYT will report EPS of $1.66 for the period ending 2026-12-31, with revenue estimated at $576M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.